Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 4
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04563299Phase 4Terminated

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

Role: lead

NCT01476449Phase 2Completed

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

Role: lead

NCT01640171Not ApplicableCompleted

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

Role: lead

All 3 trials loaded